PGR and breast carcinoma: Specifically, androgen receptor (HR = 0.55; P = 0.02), progesterone receptor (HR = 0.56; P = 0.027), CDK4 (HR = 1.68; P = 0.045), breast cancer proliferation (HR = 1.74; P = 0.034), breast cancer p53 (HR = 1.77; P = 0.029), genomic risk (HR = 1.85; P = 0.019), and homologous repair deficiency (HRD; HR = 1.9; P = 0.015) expression signatures were significantly associated with PFS (Supplementary Fig. S5).